A novel binding mode reveals two distinct classes of NMDA receptor GluN2B-selective antagonists s

Molecular Pharmacology

Volumn 89, Issue 5, 2016, Pages 541-551

  Stroebel, David ^a   Buhl, Derek L ^b   Knafels, John D ^b   Chanda, Pranab K ^b   Green, Michael ^b   Sciabola, Simone ^b   Mony, Laetitia ^a   Paoletti, Pierre ^a   Pandit, Jayvardhan ^b  

^a PSL RESEARCH UNIVERSITY   (France)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIZOCILPINE; EVT 101; IFENPRODIL; IONOTROPIC RECEPTOR ANTAGONIST; MK 22; PHENYLETHANOLAMINE; UNCLASSIFIED DRUG; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; EVT-101; HYBRID PROTEIN; IMIDAZOLE DERIVATIVE; LIGAND; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N-(3-(3-(4-METHYLBENZYL)-1,2,4-OXADIAZOL-5-YL)CYCLOPENTYL)-1H-PYRAZOLO(3,4-D)PYRIMIDIN-4-AMINE; NEW DRUG; NR2B NMDA RECEPTOR; OXADIAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN SUBUNIT; PYRIDAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; XENOPUS PROTEIN;

ARTICLE; BRAIN DISEASE; CONTROLLED STUDY; DRUG BINDING; ELECTROPHYSIOLOGY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; ALLOSTERISM; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; BIOLOGY; CHEMISTRY; CONFORMATION; DRUG EFFECTS; EXPERT SYSTEM; GENETICS; METABOLISM; MOLECULAR DOCKING; MOLECULAR MODEL; MUTATION; PROTEIN DOMAIN; PROTEIN SUBUNIT;

ADRENERGIC ALPHA-ANTAGONISTS; ALLOSTERIC REGULATION; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; COMPUTATIONAL BIOLOGY; DRUGS, INVESTIGATIONAL; EXPERT SYSTEMS; HUMANS; IMIDAZOLES; LIGANDS; MEMBRANE TRANSPORT MODULATORS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; MUTATION; OXADIAZOLES; PIPERIDINES; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN SUBUNITS; PYRIDAZINES; PYRIMIDINES; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT FUSION PROTEINS; XENOPUS PROTEINS;

EID: 84963807733     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.103036     Document Type: Article

References (63)

1. Alanine A, Bourson A, Büttelmann B, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, and Wyler R (2003) 1-Benzyloxy-4, 5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett 13:3155-3159.
2. Alanine A, Buettelmann B, Heitz-Neidart M-P, Jaeschke G, Pinard E and Wyler R (2002) inventors. Preparation of imidazole derivatives as NMDA (N-methyl-D-aspartate) receptor subtype 2B selective blockers. Patent #WO 2002060877 A1 20020808. Applicant: Hoffman La Roche, filed Jan. 21, 2002.
3. Avenet P, Léonardon J, Besnard F, Graham D, Frost J, Depoortere H, Langer SZ, and Scatton B (1996) Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes. Eur J Pharmacol 296:209-213.
4. Borza I and Domány G (2006) NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Top Med Chem 6:687-695.
5. Brown DG, Maier DL, Sylvester MA, Hoerter TN, Menhaji-Klotz E, Lasota CC, Hirata LT, Wilkins DE, Scott CW, and Trivedi S et al. (2011) 2, 6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity. Bioorg Med Chem Lett 21:3399-3403.
6. Burger PB, Yuan H, Karakas E, Geballe M, Furukawa H, Liotta DC, Snyder JP, and Traynelis SF (2012) Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators. Mol Pharmacol 82:344-359.
7. Büttelmann B, Alanine A, Bourson A, Gill R, Heitz MP, Mutel V, Pinard E, Trube G, and Wyler R (2003) 2-(3, 4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett 13:829-832.
8. Carron C, Jullien A, and Bucher B (1971) Synthesis and pharmacological properties of a series of 2-piperidino alkanol derivatives. Arzneimittelforschung 21:1992-1998.
9. Chenard BL, Bordner J, Butler TW, Chambers LK, Collins MA, De Costa DL, Ducat MF, Dumont ML, Fox CB, and Mena EE et al. (1995) (1S, 2S)-1-(4-hydroxyphenyl) - 2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J Med Chem 38:3138-3145.
10. Chenard BL and Menniti FS (1999) Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des 5:381-404.
11. Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, Schmidt AW, and Fox CB (1991) Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 34:3085-3090.
12. Chizh BA, Headley PM, and Tzschentke TM (2001) NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci 22:636-642.
13. Claiborne CF, McCauley JA, Libby BE, Curtis NR, Diggle HJ, Kulagowski JJ, Michelson SR, Anderson KD, Claremon DA, and Freidinger RM et al. (2003) Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg Med Chem Lett 13:697-700.
14. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760-763.
15. Davies DJ, Crowe M, Lucas N, Quinn J, Miller DD, Pritchard S, Grose D, Bettini E, Calcinaghi N, and Virginio C et al. (2012) A novel series of benzimidazole NR2B-selective NMDA receptor antagonists. Bioorg Med Chem Lett 22:2620-2623.
16. Durrant JD, de Oliveira CA, and McCammon JA (2011) POVME: an algorithm for measuring binding-pocket volumes. J Mol Graph Model 29:773-776.
17. Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, Heitz MP, and Kemp JA (1997) Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283:1285-1292.
18. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, and Perry JK et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739-1749.
19. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, and Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177-6196.
20. Gallagher MJ, Huang H, Pritchett DB, and Lynch DR (1996) Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem 271:9603-9611.
21. Gitto R, De Luca L, Ferro S, Buemi MR, Russo E, De Sarro G, Chisari M, Ciranna L, and Chimirri A (2012) Synthesis and biological characterization of 3-substituted 1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors. Part 2. J Med Chem 55:10532-10539.
22. Guex N and Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18:2714-2723.
23. Ibrahim L, Diaz Granados N, Jolkovsky L, Brutsche N, Luckenbaugh DA, Herring WJ, Potter WZ, and Zarate CA, Jr (2012) A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 32:551-557.
24. Kalia LV, Kalia SK, and Salter MW (2008) NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 7:742-755.
25. Karakas E and Furukawa H (2014) Crystal structure of a heterotetrameric NMDA receptor ion channel. Science 344:992-997.
26. Karakas E, Simorowski N, and Furukawa H (2009) Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit. EMBO J 28:3910-3920.
27. Karakas E, Simorowski N, and Furukawa H (2011) Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors. Nature 475:249-253.
28. Kemp JA and Tasker T (2009) inventors Methods for treating disorders using NMDA NR2B-subtype selective antagonist. Patent #WO 2009118187A1. Applicant: Evotec Neurosciences Gmbh, filed March 26, 2009.
29. Kew JN, Trube G, and Kemp JA (1996) A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol 497:761-772.
30. King D, Olson RE, Macor JE, Islam I, Thangathirupathy S, and Warrier JS (2013) inventors Preparation of substituted oxadiazoles and related compounds as selective NR2B antagonists. Patent #WO 2013049119 A1 20130404. Applicant: Bristol-Myers Squibb Co., filed Sept. 26, 2012.
31. Layton ME, Kelly MJ, 3rd, and Rodzinak KJ (2006) Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. Curr Top Med Chem 6:697-709.
32. Layton ME, Kelly MJ, 3rd, Rodzinak KJ, Sanderson PE, Young SD, Bednar RA, Dilella AG, McDonald TP, Wang H, and Mosser SD et al. (2011) Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtypeselective NMDA antagonists. ACS Chem Neurosci 2:352-362.
33. Lee CH, Lü W, Michel JC, Goehring A, Du J, Song X, and Gouaux E (2014) NMDA receptor structures reveal subunit arrangement and pore architecture. Nature 511:191-197.
34. Liverton NJ, Claiborne CF, Claremon DA, and McCauley JA (2004) inventors, Merck Sharp & Dohme Corp, assignees.3-Fluoro-piperidines as NMDA/NR2B antagonists. Patent #WO 2004/108705.
35. Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J, Paoletti P, and Kew JN (2003) Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. J Pharmacol Exp Ther 307:897-905.
36. Martel MA, Ryan TJ, Bell KF, Fowler JH, McMahon A, Al-Mubarak B, Komiyama NH, Horsburgh K, Kind PC, and Grant SG et al. (2012) The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults. Neuron 74:543-556.
37. Masuko T, Kashiwagi K, Kuno T, Nguyen ND, Pahk AJ, Fukuchi J, Igarashi K, and Williams K (1999) A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein. Mol Pharmacol 55:957-969.
38. McIntyre CJ, McCauley JA, Bednar B, Bednar RA, Butcher JW, Claremon DA, Cunningham ME, Freidinger RM, Gaul SL, and Homnick CF et al. (2009) Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists. Bioorg Med Chem Lett 19:5132-5135.
39. Milletti F, Storchi L, Sforna G, and Cruciani G (2007) New and original pKa prediction method using grid molecular interaction fields. J Chem Inf Model 47:2172-2181.
40. Mony L, Kew JN, Gunthorpe MJ, and Paoletti P (2009a) Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 157:1301-1317.
41. Mony L, Krzaczkowski L, Leonetti M, Le Goff A, Alarcon K, Neyton J, Bertrand HO, Acher F, and Paoletti P (2009b) Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors. Mol Pharmacol 75:60-74.
42. Mony L, Zhu S, Carvalho S, and Paoletti P (2011) Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines. EMBO J 30:3134-3146.
43. Monyer H, Burnashev N, Laurie DJ, Sakmann B, and Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
44. Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P, Traynelis SF, and Dingledine R (1998) Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1:659-667.
45. Nikam SS and Meltzer LT (2002) NR2B selective NMDA receptor antagonists. Curr Pharm Des 8:845-855.
46. Paoletti P (2011) Molecular basis of NMDA receptor functional diversity. Eur J Neurosci 33:1351-1365.
47. Paoletti P, Ascher P, and Neyton J (1997) High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci 17:5711-5725.
48. Paoletti P, Bellone C, and Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383-400.
49. Perin-Dureau F, Rachline J, Neyton J, and Paoletti P (2002) Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci 22:5955-5965.
50. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, and Landen JW (2008) An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631-637.
51. Sadowski J, Gasteiger J, and Klebe G (1994) Comparison of Automatic Three-Dimensional Model Builders Using 639 X-Ray Structures. J Chem Inf Comput Sci 34:1000-1008.
52. Sastry GM, Adzhigirey M, Day T, Annabhimoju R, and Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221-234.
53. Shalaeva M, Kenseth J, Lombardo F, and Bastin A (2008) Measurement of dissociation constants (pKa values) of organic compounds by multiplexed capillary electrophoresis using aqueous and cosolvent buffers. J Pharm Sci 97:2581-2606.
54. Sheng M, Cummings J, Roldan LA, Jan YN, and Jan LY (1994) Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 368:144-147.
55. Suetake-Koga S, Shimazaki T, Takamori K, Chaki S, Kanuma K, Sekiguchi Y, Suzuki T, Kikuchi T, Matsui Y, and Honda T (2006) In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist. Pharmacol Biochem Behav 84:134-141.
56. Tewes B, Frehland B, Schepmann D, Robaa D, Uengwetwanit T, Gaube F, Winckler T, Sippl W, and Wünsch B (2015) Enantiomerically pure 2-methyltetrahydro-3-benzazepin-1-ols selectively blocking GluN2B subunit containing N-methyl-D-aspartate receptors. J Med Chem 58:6293-6305.
57. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, and Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62:405-496.
58. Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, Womack T, and Bricogne G (2011) Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol Crystallogr 67:293-302.
59. Williams K (1993) Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44:851-859.
60. Yuan H, Myers SJ, Wells G, Nicholson KL, Swanger SA, Lyuboslavsky P, Tahirovic YA, Menaldino DS, Ganesh T, and Wilson LJ et al. (2015) Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects. Neuron 85:1305-1318.
61. Zhu S and Paoletti P (2015) Allosteric modulators of NMDA receptors: multiple sites and mechanisms. Curr Opin Pharmacol 20:14-23.
62. Zhu S, Riou M, Yao CA, Carvalho S, Rodriguez PC, Bensaude O, Paoletti P, and Ye S (2014) Genetically encoding a light switch in an ionotropic glutamate receptor reveals subunit-specific interfaces. Proc Natl Acad Sci USA 111:6081-6086.
63. Zhu S, Stroebel D, Yao CA, Taly A, and Paoletti P (2013) Allosteric signaling and dynamics of the clamshell-like NMDA receptor GluN1 N-terminal domain. Nat Struct Mol Biol 20:477-485.